United States Uterine Fibroid Market MRFR Unleashes the Forecast for 2018 – 2023

 

Market Overview

Uterine fibroids are the noncancerous growths of the uterus, which mostly appear during childbearing years. It is the abnormal growth of that gets developed inside or on the wall of a woman’s uterus. Uterine fibroids is also known as myomas or leiomyomas. The symptom of uterine fibroids are frequent urination, constipation, backache, heavy menstrual bleeding, pelvic pressure, or menstrual periods lasting more than a week. The women with mild symptoms may go for medical treatments such as hormonal drugs, gonadotropin agonists, progestin and oral contraceptives. Women with moderate to severe symptoms may need surgery to treat uterine fibroids. According to the U.S. Department of Health and Human Services office on Women Health, about 20% to 80% of women develop fibroids by the age of 50 and nearly 30% will get them at the age of 35. Uterine fibroids are most common in women in their 40s and early 50s.

The United States Uterine Fibroid market is showing the significant growth; mainly due to change in lifestyle mainly dietary pattern, growing number of hysterectomy surgeries. Additionally rising in aging population also leads the Uterine Fibroid market with in this region.

United States Uterine Fibroid Market Drivers:

AstraZeneca (U.K), Cook Medical Inc. (U.S.), Boston Scientific Corporation (U.S.), GE Healthcare (U.K), AbbVie Inc. (U.S.), Hologic (U.S.), CooperSurgical Inc. (U.S.), C. R. Bard, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), and Bayer AG (Germany) are some of the leading players at the cutting edge of the competition in the market of Uterine Fibroid.

Browse Complete Premium Research Report https://www.marketresearchfuture.com/reports/uterine-fibroid-market-2394  

United States Uterine Fibroid Market   - Regional Analysis

The market of Uterine Fibroid devices is much higher in the United States region, owing to its high prevalence in African- American race, change in lifestyle. According to one large cohort study of NIS on African-American women in Maryland, uterine fibroids was the cause of 65.4% of total 53,000 women undergoing hysterectomy.

Moreover, most of the major market players belong from this region, thus they introduce the advance technology firstly in the United States in comparison to others region.

About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar, Pune

+1 646 845 9312

Email: sales@marketresearchfuture.com

Comments

Post a Comment

Popular posts from this blog

Global Pompe Disease Treatment Market Global Business Investment Study and Future Trends 2019 to 2023

  Global Pompe Disease Treatment Market: Information by Type (Late-Onset Pompe Disease, Classic Infantile-Onset Pompe Disease, Non-Classic infantile-onset Pompe Disease), Therapy (Enzyme Replacement Therapy, Gene Therapy, Others), End-User (Hospitals and Clinics; Research and Academic Institutes) and Region (Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Forecast till 2030 Market Highlights Global Pompe Disease Treatment Market is expected to register a CAGR of 3.0% during the forecast period of 2019 to 2030 and was valued at USD 1,181.6 Million in 2018. Pompe disease is a genetic metabolic disorder that occurs in infants. This disease is caused due to the mutations in the GAA gene responsible for producing the acid, alpha-glucosidase enzyme that converts glycogen into a simple form. The absence or mutation in the GAA gene leads to the accumulation of glycogen and results to have a heart problem, muscle weakness, liver damage that can lead to premature death in...
Read more

Global Hematuria Treatment Market Research and Growth Analysis by Segmentation, Regional Outlook

  The Global Hematuria Treatment Market is expected to grow significantly during the forecast period (2016–2022). The presence of blood in the urine is the medical condition termed as Hematuria. Kidney stones, Urinary Tract Infection (UTI), and inherited diseases are some of the causes of hematuria. The disease is a serious issue as normal urine does not contain red blood cells (RBC). According to the American Urological Association (AUA), microscopic hematuria is defined as three or more RBC’s per high-power field on the microscopic assessment of urinary residue after two to three times of urine analysis. Avail a Free Sample@  https://www.marketresearchfuture.com/sample_request/1732 Segmentation The Global Hematuria Treatment Market has been segmented on the basis of type, causes, treatment, and end-user. On the basis of type, the market has been classified as gross or macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger’s hematuria. On the basis of ...
Read more

Global Benign positional vertigo Market Research Methodology, Forthcoming Developments and Forecast to 2023

  Market Synopsis of Global Benign positional vertigo Market: Market Scenario: global benign positional vertigo market. Increasing awareness of the disorder and treatment options are leading the market growth. Medicine, devices and accessories manufacturers are developing new products for the market. Moreover, increasing funding for R&D of advanced product development are major drivers for the market. The Global Benign Positional Vertigo Market is growing at the CAGR of ~4.0% during the forecast period and expected to reach US$ 797.3 million by 2023. Avail a Free Sample@  https://www.marketresearchfuture.com/sample_request/3234 Key Players for Global Benign positional vertigo Market:                         Some of the key players in this market are:  Ambu A/S (Denmark), DizzyFix (Canada), DizzyStop (US), Dr. Reckeweg & Co. GmbH (Germany), Ocean ...
Read more